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Abstract
Incidence of venous thromboembolism (VTE) risk varies by age and sex. Some studies have reported overall higher risk in 
men, especially when VTEs triggered by female reproductive factors are excluded. However, higher mortality rates in men 
may have led to overestimation of lifetime VTE risk in men compared with women. Therefore, we estimated the lifetime 
risk of VTE in men and women in a Danish, nationwide cohort, taking into account the competing risk of death. Within the 
population of Denmark (> 5 million persons), all first-time VTEs occurring in 1995–2016 were identified from the Danish 
National Patient Registry covering all Danish hospitals. The cumulative incidences of VTE were estimated in men and women 
with age as timescale, taking into account the competing risk of death. Estimated lifetime risk was defined as cumulative 
incidence at age 100. In a simulation study, we excluded the proportion of female cases that could be attributed to reproduc-
tive risk factors and re-estimated the cumulative incidence. We identified 123,543 incident VTEs. The cumulative incidence 
of VTE was 1.9% in women and 1.3% in men at age 50, 4.3% in women and 4.4% in men at age 70, and 9.3% in women 
and 8.1% in men at age 100. After accounting for VTEs attributed to reproductive factors, the corresponding incidences in 
women were 1.2% at age 50, 3.2% at age 70, and 8.2% at age 100. In conclusion, the estimated lifetime risk of VTE was 
slightly higher in women than in men when accounting for competing risk of death. Our simulation study suggested that 
reproductive risk factors contribute modestly to the estimated lifetime VTE risk in women.
Keywords Epidemiology · Estimated life time risk · VTE · DVT · PE · Competing risk of death · Cumulative incidence · 
Reproductive risk factors
Introduction
Previous studies of venous thromboembolism (VTE) risk 
by sex have provided inconsistent results, with some stud-
ies reporting a higher risk in women [1], some reporting a 
higher risk in men [2–4], and others finding no difference 
[5]. Incidence rates of VTE in men and women are also 
reported to vary with age, and differences in study results for 
overall VTE in men versus women are likely explained by 
differences in the age range of the populations under study 
[2, 3, 6, 7]. In younger age groups (< 50 years) the inci-
dence of VTE is higher in women than in men [7] due to 
female reproductive risk factors (e.g. oral contraceptives and 
pregnancy), while in middle-aged persons (50–70 years) the 
incidence is higher in men than in women [2, 6].
A case–control study of persons aged 18–70  years 
reported that when female reproductive factors were taken 
into account, the odds ratio was twofold higher in men than 
in women [8]. This has led to the hypothesis that men have a 
higher intrinsic risk of incident VTE than women [8]. How-
ever, female reproductive risk factors are mainly present at 
young age (< 50 years), when the baseline risk of VTE is 
low, thus resulting in a large relative, but modest absolute 
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risk increase. To date, no study has assessed VTE risk in 
men and women over the lifespan, accounting for the con-
tribution of female reproductive risk factors to lifetime risk 
in women.
The competing risk of death is another factor that can 
influence VTE risk differences in men and women [9]. 
Men have a higher mortality rate than women across all 
age groups [10, 11]. This may result in overestimation of 
VTE risk in men compared with women, particularly in the 
older age groups, which have the highest absolute difference 
in mortality rates by sex [12]. Thus, the apparently higher 
VTE risk in middle-aged and older men could potentially 
be explained by differences in mortality rates. We are aware 
of only one study that assessed the lifetime risk of VTE 
in men and women, while accounting for the competing 
risk of death. Using two US cohorts aged 45–85 years, Bell 
et al. found marginally higher cumulative VTE incidence 
in women than in men (8.4% vs. 7.7%) [13]. To our knowl-
edge, no study has assessed the age-specific cumulative inci-
dence of VTE in men and women using a nationwide cohort 
including subjects of all ages and taking into account the 
competing risk of death.
The aim of this study was to estimate the lifetime risk of 
VTE, deep vein thrombosis (DVT), and PE among men and 
women using a Danish nationwide cohort, and accounting 
for death as a competing event. Furthermore, to examine the 
hypothesis that the inherent lifetime risk of VTE is higher in 
men, we simulated how absence of female reproductive risk 
factors could influence the lifetime risk of VTE in women 
compared with the lifetime risk in men.
Methods
Setting and study population
Our study was based on data obtained from Danish health-
care and administrative registries. The Danish healthcare 
system is government-funded and provides all legal residents 
with free access to health care [14]. Complete individual-
level linkage between all health and administrative regis-
tries is enabled by the unique 10-digit identification number 
assigned by the Danish Civil Registration System (CRS) to 
all legal residents at birth or upon immigration [15]. The 
Danish National Patient Registry (DNPR), which is linked 
to the CRS, contains data on more than 99% of all inpa-
tient stays and outpatient visits to Danish hospitals. Each 
hospitalization or outpatient visit is recorded in the DNPR 
with one primary diagnosis and one or more secondary diag-
noses coded according the International Classification of 
Diseases, Tenth Revision (ICD-10) [16].
The entire population of Denmark in 1995 (N = 5,306,416) 
served as the source cohort. Individuals with a history of 
VTE before 1995 were excluded. The cohort was followed 
from January 1, 1995 through December 31, 2016. Informa-
tion on age, sex, date of emigration (when applicable), and 
death (when applicable) was obtained from the CRS.
Ascertainment of patients with venous 
thromboembolism
The DNPR was used to identify all inpatients and outpatients 
with a primary or secondary discharge diagnosis of DVT, 
PE, splanchnic vein thrombosis, or cerebral vein thrombo-
sis, based on ICD-10 diagnosis codes (listed in Supplemen-
tary Table 1), during the period January 1, 1995 through 
December 31, 2016. In patients experiencing DVT and PE 
simultaneously, only PE was counted due its greater severity.
Competing risk of death
Non-informative (i.e. independent) censoring is an assump-
tion in the traditional Kaplan–Meier survival analysis. This 
means that at each time point, subjects who remain in the 
study should have the same future risk of the disease (i.e. 
VTE) as those who have dropped out of the study (cen-
sored). However, when a person is censored due to death, the 
risk of VTE is instantly reduced to zero, and the assumption 
of non-informative censoring is therefore violated. Conse-
quently, a high risk of death will lead to an overestimation 
of VTE risk, and thus bias the results [17, 18]. The cumula-
tive incidence function (CIF) allows for estimation of the 
incidence of an outcome while taking competing risk into 
account. In the competing risk setting, only one type of event 
can occur. Thus, the occurrence of one event precludes sub-
sequent occurrence of other event types. The sum of the CIF 
estimates for each separate outcome equals the CIF estimate 
for the composite outcome comprising all the competing 
events [17].
Statistical analysis
We characterized the source cohort according to sex and age 
groups. Person-time of follow-up accrued from inclusion 
in the cohort until the date of an incident VTE, emigration 
from Denmark, death, or end of the study period (Dec 31, 
2016), whichever occurred first. To estimate incidence rates 
of VTE and death, the population was divided into five-year 
age groups ranging from 0–4 to 100 + years. Age was used 
as the time scale, and the 5-year age groups were modeled 
as time-varying covariates (i.e., individuals contributed 
person-time to different age groups as they grew older dur-
ing the study period). Incidence rates (IRs) with 95% con-
fidence intervals (CIs) for overall VTE, DVT, PE and death 
were calculated for each 5-year age group by dividing the 
number of VTEs by the person-time accrued in that specific 
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age group in men and women separately. These IRs were 
expressed as number of events per 1000 person-years (PY) 
at risk.
Cumulative incidence curves with and without death as a 
competing event were estimated using age as the time scale. 
Cumulative incidence with death as a censoring event was 
estimated using the complement of the Kaplan–Meier prod-
uct limit estimator (1-KM), while the cumulative incidence 
estimate with death as a competing event was calculated 
using CIF [19]. The estimated lifetime risk was defined as 
the CIF-estimate at age 100.
Since the incidence of VTE has increased during the last 
20 years [20], we performed sensitivity analyses to investi-
gate potential birth cohort effects in men and women. The 
study period was divided into 1995–2005 and 2006–2016, 
and cumulative incidence curves for men and women were 
created for each interval.
Simulation study to account for female reproductive 
risk factors
During their lifetimes, most women are exposed to risk fac-
tors associated with female reproduction, such as hormo-
nal contraception or pregnancy, which is known to increase 
the risk of VTE [21]. We therefore wished to simulate how 
absence of female reproductive risk factors would influence 
the cumulative incidence of VTE in women. Studies using 
relative measures have reported a twofold higher risk of 
VTE in men compared to women without reproductive risk 
factors [7, 8]. In a nationwide study of Danish women aged 
15–49, Lidegaard et al. reported an overall IR of VTE of 
4.03 per 10,000 woman-years in the total population [22]. 
The IR among former or never users of oral contraceptives 
was 3.01 per 10,000 woman-years, while the IR among cur-
rent oral contraceptive users was 6.29 per 10,000 woman-
years [22]. Based on these rates, the population-attributable 
fraction (PAF) of oral contraceptives would be 25% in the 
15–49-year age group. Similarly, a nationwide Danish study 
of pregnancy-related VTE in women aged 15–49 reported 
that the IR among non-pregnant women was 3.6 per 10,000 
woman-years, while the IR among pregnant women was 
10.7 per 10,000 woman-years [23]. This corresponded to 
an estimated PAF of pregnancy of 10%. We estimated con-
servatively that 45% of all VTE cases in the 15–49 age group 
could be attributed to oral contraceptive use or pregnancy. 
In our simulation, we therefore randomly treated 45% of the 
VTE cases in this age group as if they had never occurred 
(i.e., the proportion of female cases that could be attributed 
to reproductive risk factors) and re-estimated the CIF of 
VTE in women. The simulation approach was repeated 10 
times, to obtain an average cumulative incidence measure 
from the 10 simulations.
SAS version 9.4 (SAS Institute Inc. Cary, North Carolina, 
USA) was used to perform the statistical analyses and the 
simulation.
Results
Our study cohort consisted of 2,623,180 (49.4%) men and 
2,683,236 (50.6%) women. We identified 123,543 individu-
als with a first-time diagnosis of VTE between January 1, 
1995 and December 31, 2016. The baseline distribution 
of the study population by 5-year age groups in men and 
women is presented in Fig. 1. Among the VTEs, 73,749 
(59.7%) were DVTs and 49,794 (40.3%) were PEs. The pro-
portion of VTEs presenting as PEs was 41.4% in women and 
39.1% in men.
Incidence rates of VTE
The overall crude incidence rates of VTE were 1.28 (95% 
CI 1.27–1.29) per 1000 person-years in women and 1.17 
(95% CI 1.16–1.18) per 1000 PY in men. The incidence 
rates increased with age in both men and women. In the 
15–45-year age group, the incidence rates were higher in 
women than in men, ranging from 0.24 to 0.68 per 1000 
PY in women and from 0.07 to 0.62 per 1000 PY in men 
(Table 1). For persons aged 45 to 80 years, the rates were 
higher in men than in women (ranges: 0.85–4.16 per 1000 
PY in men and 0.79–3.94 per 1000 PY in women). In the 
oldest age groups (≥ 80 years) the rates were similar or 
slightly higher in women than in men, ranging from 4.94 to 
5.73 per 1000 PY in women and from 4.92 to 4.98 per 1000 
PY in men (Table 1). The overall incidence rate of DVT was 
0.75 (95% CI 0.74–0.76) per 1000 PY in women and 0.71 
(95% CI 0.70–0.72) per 1000 PY in men. The rate of PE was 
0.53 (95% CI 0.52–0.54) per 1000 PY in women and 0.46 
(95% CI 0.45–0.47) per 1000 PY in men. The incidence 
rates of DVT and PE followed the same patterns as those 
observed for overall VTE in men and women across all age 
groups (Supplementary Tables 1 & 2).
Death rates
Death rates in men and women by 5-year age groups are 
shown in Fig. 2. The death rates were essentially the same 
for men and women up to the age of 40 and then were con-
sistently higher in men.
Cumulative incidence of VTE
With the traditional 1-KM approach, the total cumulative 
incidences of VTE in men and women were 0.2% and 0.6% 
at age 30, 1.3% and 1.9% at age 50, 4.9% and 4.6% at age 
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70, and 17.6% and 17.4% at age 100, respectively (Fig. 3a). 
With the CIF approach, accounting for the competing risk 
of death, the estimated cumulative incidence of VTE was 
substantially lowered after the age of 65 in both sexes. The 
CIF estimates in men and women were 0.2% and 0.6% at 
age 30, 1.3% and 1.9% at age 50, 4.3% and 4.3% at age 
70, and 8.1% and 9.3% at age 100, respectively (Fig. 3b).
Fig. 1  Distribution of the study 
population at baseline inclusion 
in 1995 by sex and five-year age 
groups
Table 1  Incidence rates per 
1000 person-years of venous 
thromboembolism by five-year 
age groups in men and women
Women Men
Age (years) n Events IR (95% CI) n Events IR (95% CI)
0–4 167,754 2 0.00 (0.00–0.01) 176,096 0 –
5–9 313,930 5 0.00 (0.00–0.01) 329,681 7 0.01 (0.00–0.01)
10–14 451,067 25 0.01 (0.01–0.02) 472,786 17 0.01 (0.00–0.01)
15–19 614,941 620 0.24 (0.22–0.25) 643,523 194 0.07 (0.06–0.08)
20–24 799,829 1355 0.40 (0.38–0.43) 835,050 461 0.13 (0.12–0.14)
25–29 893,259 1927 0.55 (0.52–0.57) 935,255 706 0.19 (0.18–0.21)
30–34 929,095 2206 0.58 (0.56–0.61) 972,259 1272 0.32 (0.30–0.34)
35–39 971,995 2412 0.60 (0.58–0.62) 1,013,893 1929 0.46 (0.44–0.48)
40–44 1,003,078 2790 0.68 (0.65–0.70) 1,040,689 2652 0.62 (0.60–0.65)
45–49 1,022,809 3266 0.79 (0.77–0.82) 1,058,651 3618 0.85 (0.82–0.88)
50–54 1,002,258 3467 0.85 (0.83–0.88) 1,029,410 4652 1.12 (1.09–1.15)
55–59 925,235 3967 1.05 (1.01–1.08) 935,699 5703 1.50 (1.46–1.54)
60–64 849,920 5082 1.48 (1.44–1.52) 837,997 7029 2.09 (2.04–2.14)
65–69 767,425 6600 2.19 (2.13–2.24) 726,802 7610 2.69 (2.63–2.75)
70–74 671,501 7449 2.98 (2.91–3.05) 594,091 7425 3.44 (3.36–3.51)
75–79 544,360 8002 3.94 (3.86–4.03) 431,649 6416 4.16 (4.06–4.26)
80–84 430,778 7592 4.94 (4.83–5.05) 290,458 4772 4.92 (4.78–5.06)
85–89 296,681 5502 5.59 (5.44–5.74) 159,768 2684 5.58 (5.37–5.79)
90–94 153,877 2477 5.70 (5.47–5.92) 61,578 848 5.52 (5.14–5.89)
95–99 47,600 611 5.73 (5.27–6.18) 13,635 134 4.98 (4.13–5.82)
≥ 100 7179 44 3.65 (2.57–4.73) 1402 13 5.88 (2.68–9.07)
Total 12,864,571 65,401 1.28 (1.27–1.29) 12,560,372 58,142 1.17 (1.16–1.18)
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In subgroup analyses of DVT and PE, the 1-KM 
and CIF estimates followed the same patterns as those 
observed for overall VTE in men and women. With the 
1-KM approach, the cumulative incidence of DVT at 
age 100 was similar in men (10.0%) and women (10.1%) 
(Fig. 4a). With the CIF approach the estimated cumulative 
incidence was marginally higher in women (5.4%) than 
in men (4.9%) (Fig. 4b). A similar pattern was observed 
for PE: the cumulative incidence at age 100 was 8.1% in 
women and 8.5% in men in the regular 1-KM analysis, 
and 4.0% in women and 3.3% in men in the CIF analysis 
(Fig. 5b).
Our sensitivity analysis showed that the CIF estimates 
of VTE were higher in both sexes during 2006–2016 
compared to 1995–2005. Nevertheless, the patterns were 
similar in men and women in the two intervals, indicating 
no gender differences due to birth cohort effects (Supple-
mentary Figs. 1a & b).
Fig. 2  Death rates in men and 
women per 1000 person-years
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Fig. 3  Cumulative incidence of venous thromboembolism (VTE) by increasing age in men and women, in analyses using traditional censoring 
(1-Kaplan Meier) (Panel A) and including death as a competing event (Panel B)
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Simulation study of cumulative incidence of VTE 
to account for female reproductive risk factors
In our simulation study, in which we ignored 45% of VTEs 
occurring in the female population aged 15–49 years (the 
proportion of events that could be attributed to female 
reproductive factors), the cumulative incidence of VTE 
was 0.5% at age 30, 1.2% at age 50, 3.2% at age 70, and 
8.2% at age 100 (Fig. 6) after accounting for the compet-
ing risk of death.
Discussion
We assessed age-specific cumulative incidence and esti-
mated lifetime risk of VTE in men and women from the 
entire Danish population from 1995 to 2016, using an 
approach accounting for the competing risk of death. The 
estimated lifetime risk of VTE (cumulative incidence of 
VTE at age 100), was 9.3% in women and 8.1% in men 
based on incidence rates from a time period of approxi-
mately 20 years. Correspondingly, the estimated lifetime 
Fig. 4  Cumulative incidence of deep vein thrombosis (DVT) by increasing age in men and women in analyses using traditional censoring 
(1-Kaplan Meier) (Panel A) and including death as a competing event (Panel B)
Fig. 5  Cumulative incidence of pulmonary embolism (PE) by increasing age in men and women in analyses using traditional censoring 
(1-Kaplan Meier) (Panel A) and including death as a competing event (Panel B)
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risk of DVT was 5.4% in women and 4.9% in men, while 
the estimated lifetime risk of PE was 4.0% in women and 
3.4% in men. In the simulation study, in which we ignored 
the proportion of VTEs that could be attributed to repro-
ductive risk factors in women, we found that the estimated 
lifetime risk was similar in men and women (8.1% and 8.2%, 
respectively). Our results indicate that the overall lifetime 
risk of VTE is marginally higher in women than in men after 
accounting for sex differences in death rates. The simulation 
study suggests that while female reproductive risk factors 
influence VTE risk in young women, they have a modest 
influence on their overall lifetime VTE risk.
Previous studies on sex-specific VTE risk have reported 
that men are either equally [5] or more at risk of VTE than 
women [24]. Since the incidence rates of VTE vary sub-
stantially across different age groups in men and women, 
the comparison of rates between the sexes is highly depend-
ent on the age range of the population under study [18]. 
Moreover, when the rate of death is high from causes other 
than the disease of interest, the incidence rates of the dis-
ease are generally overestimated in traditional Kaplan–Meier 
survival analysis due to competing risks. To compare the 
lifetime risk of VTE in men and women, we therefore per-
formed our analyses on an unselected nationwide cohort of 
women and men of all ages, considering death as a compet-
ing event. We found that the 1-KM estimate at age 100 was 
highly overestimated in both sexes. This is likely explained 
by the high death rate combined with the long follow-up 
in the study, as these parameters are known to increase the 
overestimation [12, 18]. As expected, the 1-KM estimate 
was more overestimated in men than in women due to the 
higher mortality rate in men.
We are aware of only one previous study that estimated 
cumulative VTE incidence while accounting for higher 
death rates in men than in women. Bell et al. estimated the 
lifetime risk of VTE in a cohort of 19,599 men and women 
aged 45–85 years with death as a competing risk [13]. In 
line with our findings, they reported a lifetime risk of VTE 
at age 85 of 8.4% in women and 7.7% in men [13], indicat-
ing that the overall lifetime incidence of VTE is marginally 
higher in women than in men, after accounting for death as 
a competing event.
The rapid increase in cumulative incidence observed in 
women in their early twenties may be explained by expo-
sure to female reproductive risk factors, such as contracep-
tion and pregnancy. In men, we observed a steep increase 
in VTE incidence after age 50. At age 65 the proportion of 
men and women who had experienced a VTE was similar. A 
case–control study of persons aged 18–70 reported that the 
risk of a first VTE was twice as high in men than in women, 
after excluding females with reproductive risk factors [8]. 
However, the study included few females without reproduc-
tive risk factors, was based on relative measures, and the 
upper age limit was 70 years. Our study showed that half of 
all VTEs in the female population occurred after the age of 
70, i.e., at an age when women are not exposed to reproduc-
tive risk factors. Moreover, only 22% of VTEs in women 
occurred before age 50. Based on previous literature [22], 
we estimated that approximately 45% of all VTEs in this age 
group could be attributed to oral contraceptives and preg-
nancy. In our simulation, in which we treated the proportion 
of cases among young women that could be attributed to 
reproductive risk factors as if they had not occurred, we 
found that the estimated lifetime risk was 8.2% in women. 
This was similar to the estimated lifetime risk in men of 
8.1%. This indicates that even if VTEs occurring in women 
due to reproductive risk factors were avoided, the risk of 
VTE, taking a lifetime perspective, is similar in men and 
women.
A paper by Scheres et  al. [25] based on the MEGA, 
Hokusai-VTE, and RIETE studies reported sex differences 
by the anatomical location of first VTE. A higher propor-
tion of women than men presented with PE, with the differ-
ence ranging from 3.1 to 8.5 percentage points [25]. Of note, 
their findings were presented as conditional proportions, and 
not as absolute risks, which are needed to fully elucidate 
potential sex differences in presenting location. Like Scheres 
et al., we found a two-percentage-point higher proportion of 
PE among women (41.9%) than among men (39.1%) when 
considering all VTEs in the population. However, when 
expressed as absolute risks, the estimated lifetime risk was 
only marginally higher in women than in men for both PE 
(4.0% vs. 3.4%) and DVT (5.4% vs. 4.9%). Thus, our find-
ings are in line with previous studies showing that the overall 
Fig. 6  Cumulative incidence of venous thromboembolism (VTE) by 
increasing age in men and women including death as a competing 
risk, and simulated data on females excluding VTE cases caused by 
reproductive risk factors
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incidence of DVT and PE do not differ greatly in men and 
women [1, 2, 4, 6, 26].
The main strength of our study was use of an unselected 
nationwide cohort, which reduced the risks of selection and 
attrition bias that might occur in more traditional cohort 
studies. Moreover, VTE diagnoses in Denmark are usually 
made by trained specialists, and a validation study of DNPR 
data reported positive predictive values of 86% and 90% for 
diagnoses of first-time DVT and PE [27], further strength-
ening our findings. The study cohort consisted mostly of a 
homogenous Caucasian population, which reduced the likeli-
hood of confounding by ethnicity, but also may limit its gen-
eralizability beyond this population. Another concern is that 
the slight increase in incidence of VTE during recent dec-
ades could be different in men and women [20]. However, a 
Danish study on temporal trends from 2006 to 2015 reported 
the same number of new VTE cases in men and women 
[20], and our sensitivity analyses showed that cumulative 
incidence patterns in men versus women were very similar 
in the first (1995–2005) and second (2006–2016) intervals 
of the study period. Unfortunately, we could not follow a 
closed cohort from birth to death, but estimated lifetime risk 
in a Nationwide cohort of all ages followed over 20 years. 
Even though we used age as time scale, included participants 
within the entire age range, and assessed whether there were 
sex-differences in cumulative incidence during follow-up, 
we cannot rule out potential presence of birth cohort effects 
that could differ in men and women. Another potential weak-
ness of our study is that precise information on pregnancy 
and oral contraceptive use was not available in our database. 
However, Lidegaard et al.’s studies, which are derived from 
the same source population, indicated that 35–45% of VTEs 
in the 15–49 age group could be attributed to reproductive 
risk factors. Our simulation approach may be justified fur-
ther by the exposure of the majority of young women either 
to oral contraceptive use and/or pregnancy during their 
lifetime. Restriction of the study population to women who 
were never exposed to such factors would result in a small 
and extremely selected population, which is unlikely to be 
representative of young women in general.
In conclusion, we found that when the competing risk of 
death was taken into account, the estimated lifetime risk of 
VTE, DVT and PE was marginally higher in women than in 
men. Furthermore, when VTEs that could be attributed to 
female reproductive risk factors were accounted for in a sim-
ulation study, the estimated lifetime risk of VTE was simi-
lar in men and women, indicating that the contribution of 
reproductive risk factors to the overall lifetime risk of VTE 
in women is modest. Our findings challenge previous stud-
ies reporting a twofold higher risk of first-time VTE in men 
compared to women without reproductive risk factors, and 
studies reporting a higher proportion of PEs in women than 
in men. Finally, our observation of 8–10% estimated lifetime 
risk of VTE in women and men highlights the importance of 
improved primary prevention in both sexes.
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